Tazarotene
(Synonyms: 他扎罗汀; AGN 190168) 目录号 : GC15459A retinoid prodrug
Cas No.:118292-40-3
Sample solution is provided at 25 µL, 10mM.
Tazarotene, one of the acetylenic class of retinoids, is the 3rd-generation prescription topical retinoid. It is approved for treating psoriasis, acne, and photo damaged skin [1].
Tazarotene act as a retinoid prodrug and it is converted to free acid form by rapid deesterification when used in man and animals. Tazarotenic acid shows selectivity for (RAR)-β, and (RAR)-γ though it could bind to all three classes of the retinoic acid receptor (RAR) family, and this may modify gene expression.
Tazarotene mediates these effects by regulating gene transcription. Five nonsmall cell lung carcinoma (NSCLC) cell lines and the constitutive and all-trans retinoic acid (ATRA)-inducible expression of tazarotene-induced gene3 mRNA of the five head and neck squamous cell carcinoma (HNSCC) were examined to determine whether it is associated with their responsiveness to ATRA. Consequently, ATRA induced tazarotene-induced gene3 mRNA from 6 to 12h in most of the responsive cells. Depending on the cell line, the concentration of ATRA required for induction of tazarotene-induced gene3 was ranged from 1 to 500 nm [2].
67 patients aging from 13 to 30 with facial acne attended a study to evaluate the safety and efficacy of topical tazarotene 0.1% cream in the treatment of facial acne. Patients were instructed to apply topical tazarotene cream (0.1%) as a thin film over the affected part in the evening once a day for 12 weeks. And follow-ups were done at 2nd, 4th, 8th and 12th week. As a result, 53% of the patients got remission, 9% had good response, 34% had poor response and 4% of the patients by 12 weeks of treatment was no response. Topical tazarotene cream (0.1%) is an effective and safe treatment method for the face affected by acne vulgaris [3].
References:
[1]. Orlandi A ,Bianchi L, Costanzo A, et al. Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene. Journal of Investigative Dermatology, 2004, 122(4): 1037-1041.
[2]. Higuchi E, Chandraratna RAS, Hong, WK, et al. Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype. Oncogene, 2003, 22(30): 4627-4635.
[3]. Zakaria AS, Paul HK, Rahman MA George S K, et al. Topical tazarotene cream (0.1%) in the treatment of facial acne: an open clinical trial. Bangladesh Med Res Counc Bull, 2010, 36(2): 43-46.
Cas No. | 118292-40-3 | SDF | |
别名 | 他扎罗汀; AGN 190168 | ||
化学名 | ethyl 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylate | ||
Canonical SMILES | CCOC(=O)C1=CN=C(C=C1)C#CC2=CC3=C(C=C2)SCCC3(C)C | ||
分子式 | C21H21NO2S | 分子量 | 351.46 |
溶解度 | ≥ 14.85mg/mL in DMSO, ≥ 11.1 mg/mL in EtOH with ultrasonic | 储存条件 | Store at 2-8°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.8453 mL | 14.2264 mL | 28.4527 mL |
5 mM | 0.5691 mL | 2.8453 mL | 5.6905 mL |
10 mM | 0.2845 mL | 1.4226 mL | 2.8453 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: 99.95%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet